Cross Country Healthcare (CCRN)
(Delayed Data from NSDQ)
$17.14 USD
-0.26 (-1.49%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $17.15 +0.01 (0.06%) 7:58 PM ET
5-Strong Sell of 5 5
A Value B Growth D Momentum A VGM
Income Statements
Fiscal Year end for Cross Country Healthcare, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 2,020 | 2,807 | 1,677 | 836 | 822 |
Cost Of Goods | 1,569 | 2,179 | 1,302 | 634 | 618 |
Gross Profit | 450 | 628 | 375 | 203 | 204 |
Selling & Adminstrative & Depr. & Amort Expenses | 338 | 355 | 236 | 212 | 220 |
Income After Depreciation & Amortization | 113 | 273 | 139 | -9 | -16 |
Non-Operating Income | -2 | -2 | 1 | 0 | -3 |
Interest Expense | 8 | 14 | 7 | 3 | 5 |
Pretax Income | 103 | 256 | 133 | -12 | -24 |
Income Taxes | 30 | 68 | 1 | 0 | 32 |
Minority Interest | 0 | 0 | 0 | 1 | 2 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | 73 | 188 | 132 | -12 | -56 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | 73 | 188 | 132 | -13 | -58 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 131 | 286 | 149 | 4 | -1 |
Depreciation & Amortization (Cash Flow) | 18 | 13 | 10 | 13 | 15 |
Income After Depreciation & Amortization | 113 | 273 | 139 | -9 | -16 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 35.48 | 37.54 | 37.39 | 36.09 | 35.82 |
Diluted EPS Before Non-Recurring Items | 2.23 | 5.27 | 3.06 | 0.46 | 0.15 |
Diluted Net EPS (GAAP) | 2.05 | 5.02 | 3.53 | -0.36 | -1.61 |
Fiscal Year end for Cross Country Healthcare, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 414.04 | 442.29 | 540.70 | 622.71 |
Cost Of Goods | NA | 323.55 | 344.93 | 417.56 | 483.28 |
Gross Profit | NA | 90.49 | 97.36 | 123.14 | 139.42 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 77.06 | 77.06 | 87.95 | 95.62 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 13.43 | 20.30 | 35.19 | 43.80 |
Non-Operating Income | NA | 0.13 | -0.13 | -1.73 | 0.01 |
Interest Expense | NA | 0.59 | 0.67 | 3.15 | 3.69 |
Pretax Income | NA | 12.97 | 19.50 | 30.31 | 40.12 |
Income Taxes | NA | 3.93 | 6.69 | 8.96 | 10.68 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | 9.04 | 12.81 | 21.35 | 29.44 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | 9.04 | 12.81 | 21.35 | 29.44 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 34.69 | 35.15 | 35.52 | 36.56 |
Diluted EPS Before Non-Recurring Items | NA | 0.29 | 0.39 | 0.69 | 0.84 |
Diluted Net EPS (GAAP) | NA | 0.28 | 0.36 | 0.60 | 0.81 |